Cardinal Health (CAH)
(Delayed Data from NYSE)
$98.46 USD
-0.62 (-0.63%)
Updated May 20, 2024 04:00 PM ET
After-Market: $98.46 0.00 (0.00%) 7:18 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$98.46 USD
-0.62 (-0.63%)
Updated May 20, 2024 04:00 PM ET
After-Market: $98.46 0.00 (0.00%) 7:18 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Options Traders Expect Huge Moves in Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) needs investors to pay close attention to the stock based on moves in the options market lately.
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) is likely to witness solid growth in the core Pharmaceutical segment in Q4 results. However, lackluster performance in the Cordis unit is likely to mar prospects.
Here's Why You Should Hold Onto Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health's (CAH) unique portfolio of Medical and Pharmaceutical offerings will lend it a competitive edge in the MedTech space. However, the company faces sluggishness in the exam-gloves unit.
Is Cardinal Health (CAH) a Great Stock for Value Investors?
by Zacks Equity Research
Cardinal Health (CAH) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.
Amazon Forays Into Pharmacy Business: Red Alert for Others?
by Sweta Jaiswal
Amazon's entry into the high-potential pharmaceutical industry deals a blow to share prices of major players.
Why Is Cardinal Health (CAH) Up 2.5% Since Its Last Earnings Report?
by Zacks Equity Research
Cardinal Health (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Cardinal Health (CAH) Could Be Positioned for a Slump
by Zacks Equity Research
Cardinal Health (CAH) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
Cardinal Health (CAH) Misses on Earnings in Q3, Beats Revenue
by Zacks Equity Research
Cardinal Health's (CAH) adjusted earnings decreased 9.2% on a year-over-year basis to $1.39 per share.
Is Cardinal Health (CAH) a Great Stock for Value Investors Right Now?
by Zacks Equity Research
Let's put Cardinal Health (CAH) stock into this equation and find out if it is a good choice for value-oriented investors right now.
Cardinal Health (CAH) Up 7.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Cardinal Health (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Lockheed Martin, Raytheon and Cardinal Health
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Lockheed Martin, Raytheon and Cardinal Health
M&A Continues to Fuel Market
by Fred Lovely
One of the best kept secrets of this US stock market is the shrinking share count available to investors to purchase.
Cardinal (CAH) Beats on Q2 Earnings and Revenues
by Sreyoshi Mukherjee
Cardinal Health (CAH) gains on strong segmental performances in fiscal Q3 18.
Cardinal Health (CAH) Tops Q1 Earnings, Misses on Sales
by Zacks Equity Research
Cardinal Health's (CAH) pharmaceutical segment revenues increased in the first quarter due to strong growth from the Specialty business and higher number of Pharmaceutical Distribution business customers.
What's in Store for Cardinal Health (CAH) in Q1 Earnings?
by Zacks Equity Research
Cardinal Health (CAH), a global player in the healthcare services and products space, has been grappling with pricing deflation in the generics segment in the first quarter.
Why Is Cardinal Health (CAH) Down 2.7% Since the Last Earnings Report?
by Zacks Equity Research
Cardinal Health (CAH) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardinal Health (CAH) Beats on Earnings & Revenues in Q4
by Zacks Equity Research
Cardinal Health (CAH) reported strong fourth quarter results, beating the Zacks consensus estimate on both counts. Solid growth in the company's Pharmaceutical and Medical segments were the key catalysts.
Cardinal Health (CAH) Tops Q3 Earnings, Miss on Revenues
by Zacks Equity Research
Cardinal Health???s adjusted earnings rose 7% on a year-over-year basis to $1.53 per share.
Medical Product Stocks' Earnings Due on May 1: CAH & OCPNY
by Zacks Equity Research
Here we take a look at two major Medical Product bigwigs, which are expected to release their earnings results on May 1.
Why Cardinal Health (CAH) Might Surprise This Earnings Season
by Zacks Equity Research
Cardinal Health (CAH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Is Cardinal Health (CAH) Up 4.4% Since the Last Earnings Report?
by Zacks Equity Research
Cardinal Health (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardinal Health (CAH) Q2 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Cardinal Health Inc. (CAH) reported second-quarter fiscal 2017 adjusted earnings of $1.34 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 3% on a year-over-year basis.
Cardinal Health (CAH) Tops Q2 Earnings, Miss on Revenues
by Zacks Equity Research
Cardinal Health???s adjusted earnings rose 3% on a year-over-year basis to $1.34 per share.
Start the Week with These Perfect Earnings Charts
by Tracey Ryniec
Who's been able to beat earnings every quarter for 5 years?
Cardinal Health (CAH) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Cardinal Health (CAH), a global player in the healthcare services and products space, is set to report second-quarter fiscal 2017 results on Feb 7, before the bell.